Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Pfizer naming Colm Burke .
Filed returns
20
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Jan–Apr 2026 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV vaccination for older adults (Public policy or programme) | 19 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Ireland's medicine reimbursement system and funding for access to new medicines and vaccines (Matters involving public funds) | 9 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Trade | Raise concern about the impact of potential tariffs and related geo-political issues related to the pharmaceutical industry and pricing of medicines globally (Public policy or programme) | 11 | On lobbying.ie |
| May–Aug 2025 | Pfizer | Health | Expansion of the National Immunisation Programme to include RSV protection for infants and older adults (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | EU Affairs | EU Pharmaceutical Legislation proposals (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2024 | Pfizer | Health | Ireland's medicine reimbursement system and access to new medicines and vaccines (Matters involving public funds) | 14 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Economic Development and Industry | Welcomed committment to corporation tax policy and a supportive environment for FDI as outlined in the Programme for Government (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Highlighted discussions on extension of industry Supply Agreement and the importance of ensuring expenditure is efficently managed to ensure Irish patients can access innovative medicines; welcomed plans to progress the… (Public policy or programme) | 28 | On lobbying.ie |
| May–Aug 2020 | Pfizer | Health | Provided information about Pfizer's research into a COVID-19 vaccine, meeting sought with MoH/DoH. (Public policy or programme) | 29 | On lobbying.ie |
| Jan–Apr 2018 | Pfizer | Taxation | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 21 | On lobbying.ie |
| Sep–Dec 2017 | Pfizer | Health | Pfizer launched 'MBC: A Call to Action' to highlight the unmet needs of metastatic breast cancer patients. MBC is an advanced form of breast cancer where early detection does not improve survival. Even if diagnosed with… (Public policy or programme) | 14 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Health | Ireland has now become one of the slowest countries in Europe to reimburse innovative medicines for patients. HTA assessment is prolonged and decisions after HTA are exceptionally slow with the majority of medicines… (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant administrative and cost burden for five… (Legislation) | 11 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Economic Development and Industry | Global competition for FDI and life sciences investment continues to intensify and Ireland continues to compete for such investment. Pfizer has extensive operations in Ireland where many of Pfizer's leading and newest… (Public policy or programme) | 7 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Health | Pfizer is seeking reimbursement for a new treatment for metastatic breast cancer. Metastatic breast cancer is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if… (Matters involving public funds) | 8 | On lobbying.ie |
| Jan–Apr 2017 | Pfizer | Economic Development and Industry | The Companies Act 2014 allowed for a Ministerial exemption from changing a company name to include the word 'unlimited' in the company name. This change would create significant administrative and cost burden for five… (Legislation) | 17 | On lobbying.ie |
| May–Aug 2016 | Pfizer | Health | A Supply Agreement between the pharmaceutical industry and the goverment expired and a new Agreement was to be negotiated between the pharmaceutical industry and the DoH/State. (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2016 | Pfizer | Health | raise awareness of metastatic breast cancer which is an advanced form of breast cancer where early detection unfortunately does not improve survival. Even if diagnosed early, 30% of women diagnosed with early breast… (Public policy or programme) | 4 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 13 | 65.0% | |
| Economic Development and Industry | 4 | 20.0% | |
| EU Affairs | 1 | 5.0% | |
| Taxation | 1 | 5.0% | |
| Trade | 1 | 5.0% |